ArticleAesthetic surgery journal. Open forum2025
Real-World Outcomes of a Novel Botulinum Toxin A for Upper Face Aesthetics: Insights From Routine Clinical Practice.
Article in Aesthetic surgery journal. Open forum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aging signs of the upper face result from complex interactions among facial muscles and include forehead lines, glabellar lines, and crow's feet. Botulinum neurotoxin type A (BoNT-A) injections are widely utilized to address these concerns. An optimal treatment strategy should consider the interplay between elevator and depressor muscles. Comprehensive treatment approaches targeting the comprehensive upper face are gaining popularity but remain underreported in the context of newer products such as letibotulinumtoxinA. Objectives: The aim of this study is to evaluate the efficacy and safety of a comprehensive upper-face treatment using letibotulinumtoxinA (Letybo) and to assess its effect on glabellar lines, forehead lines, and crow's feet using validated clinical scales. Methods: In this prospective, observational study, 20 participants (mean age: 35.8 ± 9.3 years) received standardized injections totaling 64 units. Treatment included 16 intramuscular injections: glabella (5 sites), forehead (5 sites), and crow's feet (3 per side), with 4 units (0.1 mL) per site. Efficacy was evaluated at baseline, Week 2, and Week 16 using the Facial Wrinkle Scale, Clinician's Dynamic Forehead Line Assessment Scale, and Clinician's Dynamic Crow's Feet Assessment Scale. Results: At Week 2, ≥2-point improvement was observed in 95% of glabellar, 90% of forehead, and 90% of crow's feet cases. At Week 16, ≥1-point improvements persisted in 70% to 80% of participants. Five participants (25%) required a touch-up at Week 2. No adverse drug reactions were reported. Conclusions: Comprehensive upper-face treatment with letibotulinumtoxinA showed meaningful, sustained aesthetic improvement with good tolerability. These findings support further research in larger populations. Level of Evidence 4 Therapeutic:
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.